Work

Effect of Telomerase Peptide Vaccination, GV 1001 Combined with Gemcitabine in Treatment of Pancreatic Ductal Adenocarcinoma

Year: 2014
Type: dissertation
Abstract: Introduction: Pancreatic ductal adenocarcinoma (PDAC) shows dismal prognosis due to early metastasis, frequent recurrence and chemo-resistance. However, there is no effective treatment to overcome these problems. GV1001 is a telomerase-based cancer vaccine made of a 16-mer TERT peptide and human telomerase reverse transcriptase (hTERT), the rate-limiting subunit of the telomerase complex, is therefore an attractive target for cancer vaccination. The aim of this study was to evaluate the combination benefit of telomerase peptide vaccination, GV1001 combined with gemcitabine in PDAC.\nMethods: Human pancreatic cancer cell lines (Panc-1 and AsPC-1) were used in vitro experiment and also, PDAC xenograft mice model was established using pancreatic cancer cell lines (Panc-1 and AsPC-1). Treatment groups were divided as follows
Author: 박주경
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W3130278359
Cites: 50
Cited by:
Related to: 10